

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of the claims in the application:

**Listing of Claims:**

Claim 1 (currently amended): A substantially purified polypeptide comprising:  
(a) an amino acid sequence set forth as SEQ ID NO: 14; ~~or~~  
(b) ~~an immunogenic polypeptide comprising an immunogenic epitope of eight to ten consecutive amino acids of a polypeptide comprising the amino acid sequence set forth as SEQ ID NO: 14.~~

Claim 2 (canceled).

Claim 3 (currently amended): A substantially purified polypeptide consisting of eight to comprising at least ten consecutive amino acids of the amino acid sequence as set forth as SEQ ID NO: 14, wherein the polypeptide has a leucine or a methionine at the second position and valine or leucine in the last position, and wherein the polypeptide specifically binds HLA-A2.

Claim 4 (currently amended): A substantially purified fusion polypeptide comprising the polypeptide of claim 3 and a second heterologous polypeptide moiety ~~an amino acid sequence with at least 90% sequence identity to the amino acid sequence set forth as SEQ ID NO: 14 wherein the polypeptide is expressed in prostate cancer cells, breast cancer cells, or both.~~

Claim 5 (canceled).

Claim 6 (previously presented): A composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.

Claims 7-9 (canceled).

Claim 10 (previously presented): A substantially purified recombinant nucleic acid molecule encoding the polypeptide of claim 1.

Claims 11-14 (canceled).

Claim 15 (previously presented): The substantially purified recombinant nucleic acid molecule of claim 10, operably linked to a promoter.

Claim 16 (currently amended): ~~The~~ A substantially purified recombinant nucleic acid molecule encoding the polypeptide of claim 3 of claim 15, wherein the nucleotide sequence encodes a polypeptide comprising the amino acid sequence as set forth as SEQ ID NO: 14.

Claim 17 (currently amended): ~~The~~ A substantially purified recombinant nucleic acid molecule ~~of claim 15, wherein the nucleotide sequence encodes a polypeptide comprising an immunogenic epitope of eight to ten consecutive amino acids of the amino acid sequence as set forth as SEQ ID NO: 14~~ encoding the polypeptide of claim 4.

Claims 18-19 (canceled).

Claim 20 (currently amended): A method for eliciting an immune response in a subject, comprising administering to a subject a pharmaceutical composition, comprising:

(a) the polypeptide of claim 1; or

(b) a substantially purified polypeptide consisting of eight to ten consecutive amino acids of the amino acid sequence as set forth as SEQ ID NO: 14, wherein the polypeptide has a leucine or a methionine at the second position and valine or leucine in the last position, and wherein the polypeptide specifically binds HLA-A2; ~~nucleic acid encoding the polypeptide of claim 1 in an expression vector;~~

(c) ~~an antigen presenting cell pulsed with polypeptide comprising an epitope of the polypeptide of claim 1, or an immunogenic fragment thereof~~

in a pharmaceutically acceptable carrier, thereby eliciting ~~an~~ the immune response in the subject.

Claims 21-23 (canceled).

Claim 24 (previously presented): The method of claim 20 wherein the subject has prostate cancer.

Claim 25 (previously presented): The method of claim 20, wherein the subject has breast cancer.

Claim 26 (currently amended): The method of claim 20, ~~wherein the subject is a female at risk for developing breast cancer wherein the composition is administered to a female subject to provide an immune defense in the event that a TARP-expressing breast cancer later develops in the female.~~

Claim 27 (currently amended): The method of claim 20 ~~wherein the administered composition further comprises~~ comprising administering to the subject CD8+ cells that are sensitized with antigen presenting cells pulsed with (a) a polypeptide ~~comprising~~ consisting of an epitope of eight to ten consecutive amino acids of the protein having an amino acid sequence as set forth as SEQ ID NO: 14 or (b) a polypeptide consisting of an epitope of eight to ten consecutive amino acids of the protein having an amino acid set forth as SEQ ID NO: 14 and a second heterologous polypeptide moiety.

Claim 28 (previously presented): The method of claim 20, further comprising co-administering to the subject an immune adjuvant selected from the group consisting of a non-specific immune adjuvant, a subcellular microbial product and fraction, a hapten, an immunogenic protein, an immunomodulator, an interferon, a thymic hormone, and a colony stimulating factor.

Claims 29-33 (canceled).

Claim 34 (previously presented): The method of claim 27 wherein the CD8+ cells are cytotoxic T lymphocytes.

Claim 35 (previously presented): The method of claim 34 wherein the cytotoxic T lymphocytes are tumor infiltrating lymphocytes.

Claims 36-44 (canceled).

Claim 45 (currently amended): The substantially purified polypeptide of claim 4 ~~[[1]], wherein the second heterologous polypeptide moiety is selected from the group consisting of a polypeptide tag for isolation, a carrier protein, and a linker comprises the amino acid sequence set forth as SEQ ID NO: 14.~~

Claim 46 (previously presented): The nucleic acid of claim 10, comprising the nucleic acid sequence as set forth as SEQ ID NO: 13.

Claim 47 (previously presented): A vector comprising the nucleic acid of claim 15.

Claims 48-55 (canceled).

Claim 56 (previously presented): A nucleic acid encoding the polypeptide of claim 4.

Claim 57 (previously presented): The nucleic acid of claim 56, operably linked to a promoter.

Claim 58 (currently amended): A method for eliciting an immune response in a subject, comprising administering to a subject a composition, comprising~~[[:]~~

~~(a) a therapeutically effective amount of the polypeptide of claim 4~~

~~(b) a substantially purified nucleic acid encoding the polypeptide of claim 4 in an expression vector~~

~~(e) an antigen presenting cell pulsed with a polypeptide comprising an immunogenic epitope of eight to ten consecutive amino acids of the polypeptide of claim 4, thereof~~  
thereby eliciting an the immune response in the subject.

Claim 59 (new): The substantially purified recombinant nucleic acid molecule of claim 16, operably linked to a promoter.

Claim 60 (new): The substantially purified recombinant nucleic acid molecule of claim 17, operably linked to a promoter.

Claim 61 (new): A vector comprising the substantially purified recombinant nucleic acid molecule of claim 15.

Claim 62 (new): A vector comprising the substantially purified recombinant nucleic acid molecule of claim 59.

Claim 63 (new): A vector comprising the substantially purified recombinant nucleic acid molecule of claim 60.

Claim 64 (new): A composition comprising the polypeptide of claim 3 and a pharmaceutically acceptable carrier.

Claim 65 (new): A composition comprising the polypeptide of claim 4 and a pharmaceutically acceptable carrier.

Claim 66 (new): The method of claim 20, comprising administering the polypeptide of claim 1.

Claim 67 (new): The method of claim 20, comprising administering a substantially purified polypeptide consisting of at eight to ten consecutive amino acids of the amino acid

sequence as set forth as SEQ ID NO: 14, wherein the polypeptide has a leucine or a methionine at the second position and valine or leucine in the last position, and wherein the polypeptide specifically binds HLA-A2.

Claim 68 (new): The method of claim 67, wherein the subject is administered a fusion polypeptide comprising the polypeptide consisting of at eight to ten consecutive amino acids of the amino acid sequence as set forth as SEQ ID NO: 14, wherein the polypeptide has a leucine or a methionine at the second position and valine or leucine in the last position, and wherein the polypeptide specifically binds HLA-A2 and a second heterologous polypeptide moiety.